Revenue YoY
+11.22%
Operating Income YoY
+11.38%
Net Income YoY
+16.20%
Net Margin Δ
+77 bps
Net income bridge for West Pharmaceutical Services (WST) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Net income: $75.50M+16.20%
Profit bridge breakdown for West Pharmaceutical Services (WST) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Net Income | $467.20M | — |
| Revenue | $324.80M | +430.2% |
| Cost of Revenue | −$161.40M | -213.8% |
| Operating Expenses | −$95.40M | -126.4% |
| Other Income / Expense | $31.10M | +41.2% |
| Income Tax | −$27.00M | -35.8% |
| Other Items | $3.40M | +4.5% |
| Net Income | $542.70M | — |
- Prior Net Income$467.20M
- Revenue$324.80M
- Cost of Revenue−$161.40M
- Operating Expenses−$95.40M
- Other Income / Expense$31.10M
- Income Tax−$27.00M
- Other Items$3.40M
- Net Income$542.70M
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want the full P&L structure?Income Statement Waterfall
Frequently asked questions
Data & methodology
West Pharmaceutical Services (WST) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement